Effect of immuno-oncology on clinical and economic outcomes for a selection of cancers in Italy
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2493130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Beatrice Canali und 13 weiteren Autor:innen. Beteiligte Einrichtung: Real World Solutions, IQVIA Solutions Italy S.r.l, Milan, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Kidney Neoplasms, Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol Myers Squibb Company Italy.
Abstract (Originalsprache)
OBJECTIVES: This study assesses the impact of immune-oncology (IO) drugs' availability on cancer incidence-adjusted mortality rates from melanoma, lung, and renal cancers at population level in Italy between 2008 and 2019. METHODS: We conducted a retrospective study on cross-sectional time-series aggregated data collected from publicly available sources and IQVIA proprietary databases. Three fixed-effects regression models were used to estimate how IO availability affects incidence-adjusted mortality for each cancer type. Estimated deaths were compared with deaths in a scenario with no IO drugs availability. Finally, the number of averted deaths was valued using the human capital approach. RESULTS: A 1% increase in IO availability reduces incidence-adjusted mortality rates for melanoma, lung, and renal cancers by 0.125% (95% CI: 0.138-0.112; p < 0.01), 0.011% (95% CI: 0.013-0.009; p < 0.01) and 0.005% (95% CI: 0.006-0.003; p < 0.01) between the introduction of the drug in the therapeutic area and 2019. This reduction resulted in total savings of € 49.0 million, € 61.3 million, and € 10.9 million in indirect costs due to premature mortality, respectively. CONCLUSIONS: IO drugs introduction in Italy between 2008 and 2019 was associated with a significant decrease in deaths from each cancer and, consequently, in savings in indirect costs related to premature mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Real World Solutions, IQVIA Solutions Italy S.r.l, Milan, Italy.
- Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy.
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Medicine and Technological Innovation, Università degli Studi dell'Insubria, Varese, Italy.
- Medical Oncology Division, ASST Sette Laghi, Varese, Italy.
ORCID-Profile: Beatrice Canali, Giovanni Apolone, Paolo A Ascierto, Filippo De Braud, Francesco Grossi, Francesca Fiorentino, Alessandra Di Costanzo, Laura Candelora
Förderung
- Bristol Myers Squibb Company Italy
Zitieren
APA
Canali, B., Apolone, G., Ascierto, P. A., De Braud, F., Grossi, F., Perrone, F., Fiorentino, F., Di Costanzo, A., Candelora, L., Patanè, G., Zapparelli, G., Mezzanotte, C., Didoni, G., & Riccaboni, M. (2025). Effect of immuno-oncology on clinical and economic outcomes for a selection of cancers in Italy. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2493130
Vancouver
Canali B, Apolone G, Ascierto PA, De Braud F, Grossi F, Perrone F, et al. Effect of immuno-oncology on clinical and economic outcomes for a selection of cancers in Italy. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2493130
BibTeX
@article{Canali2025,
author = {Canali, Beatrice and Apolone, Giovanni and Ascierto, Paolo A and De Braud, Filippo and Grossi, Francesco and Perrone, Francesco and Fiorentino, Francesca and Di Costanzo, Alessandra and Candelora, Laura and Patanè, Giovanni and Zapparelli, Giuseppina and Mezzanotte, Claudia and Didoni, Guido and Riccaboni, Massimo},
title = {Effect of immuno-oncology on clinical and economic outcomes for a selection of cancers in Italy},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2493130}
}
EUVIMED